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Abstract: The viral protein 1 unique region (VP1u) of human parvovirus B19 (B19V) is a multifunctional
capsid protein with essential roles in virus tropism, uptake, and subcellular trafficking. These functions
reside on hidden protein domains, which become accessible upon interaction with cell membrane
receptors. A receptor-binding domain (RBD) in VP1u is responsible for the specific targeting and uptake
of the virus exclusively into cells of the erythroid lineage in the bone marrow. A phospholipase A2
domain promotes the endosomal escape of the incoming virus. The VP1u is also the immunodominant
region of the capsid as it is the target of neutralizing antibodies. For all these reasons, the VP1u
has raised great interest in antiviral research and vaccinology. Besides the essential functions in
B19V infection, the remarkable erythroid specificity of the VP1u makes it a unique erythroid cell
surface biomarker. Moreover, the demonstrated capacity of the VP1u to deliver diverse cargo
specifically to cells around the proerythroblast differentiation stage, including erythroleukemic cells,
offers novel therapeutic opportunities for erythroid-specific drug delivery. In this review, we focus on
the multifunctional role of the VP1u in B19V infection and explore its potential in diagnostics and
erythroid-specific therapeutics.
Keywords: parvovirus B19; B19V; VP1u; receptor; PLA2; virus entry; erythroid cells; biomarker;
drug delivery; nanocarrier
1. Introduction
The Parvoviridae is a family of nonenveloped viruses that packages a linear, single-stranded
DNA genome (~5 kb) within a small (~25 nm) icosahedral capsid. As a direct consequence of
their limited coding potential, parvoviruses are particularly dependent on host cellular factors for
their replication [1,2]. Parvoviruses are widely spread in nature and their host range might span
the entire animal kingdom [3]. Depending on their host, members of the family Parvoviridae are
subdivided into the subfamilies Parvovirinae, infecting vertebrates and Densovirinae, infecting insects
and other arthropods. Viruses that infect vertebrates, including humans, are further divided into
the dependoparvoviruses and the autonomous parvoviruses [4]. The dependoparvoviruses replicate
only in the presence of a helper virus, such as adenovirus or herpesvirus. The adeno-associated
viruses (AAVs) are not linked with any known pathology, have a wide tissue specificity, and replicate
in dividing and nondividing cells. These properties make AAVs useful gene transfer vehicles for
therapeutic applications [5]. Although autonomous parvoviruses use similar strategies for cell entry
and replication, they differ substantially in their pathogenic potential, which ranges from subclinical to
severe or even lethal infections [2]. As autonomous parvoviruses can only replicate in dividing cells,
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when the host cell DNA replication machinery becomes available, they tend to cause more severe
infections in young than in adult hosts.
While most ssDNA viruses show a circular genome structure, parvoviruses have a linear genome,
that is typically organized in two open reading frames (ORFs). The ORFs are flanked by palindromic
sequences of variable length, which fold into hairpin structures and are essential for replication [6,7].
The 5′ ORF (ns or rep gene) encodes for the regulatory nonstructural protein(s) required for viral
DNA replication and packaging. The 3′ ORF (cap gene) encodes two to four variants of a single
capsid protein (VP). Following a principle of genetic economy, the different VPs are generated by
alternative splicing or alternative codon usage, but also by post-translational proteolytic processing
during entry, resulting in a common C-terminal sequence but different N-terminal extensions of
variable length [8–10]. The T = 1 icosahedral parvovirus capsid is assembled from 60 VPs, however,
the number of N-terminal VP variants used to assemble the infectious particles varies from two (VP1
and VP2) to four (VP1–VP4) depending on the genus. The VP variants are numbered in order of
length, with VP1 being the largest variant. The common C-terminal region of the VPs forms the capsid
shell, which consists of a conserved alpha-helix and a jelly roll motif containing eight antiparallel
β-strands. The different configurations of the loops connecting the conserved β-strands delineate the
surface topology, which is characteristic to each parvovirus genus and define the virus tropism and
antigenicity [11]. Despite low sequence identity, the parvovirus capsids display structural features
that are conserved across different genera, i.e., a narrow depression at the twofold axis of symmetry,
protrusions of variable size and shape at the threefold axis and a canyon-like structure encircling a
cylindrical pore at the fivefold axis connecting with the interior of the capsid.
The minor protein VP1 has an N-terminal extension of variable length, the so-called VP1-unique
region (VP1u), and is present at 3 to 10 copies per virion depending on the parvovirus genus. VP1u is
not required for virus assembly but contains several essential motifs required for the infection. Nuclear
localization signals (NLSs) consisting of a stretch of basic amino acids have been identified in the VP1u
from several parvoviruses. These motifs were shown to confer nuclear import potential to the incoming
particles [12–19]. Another motif found in VP1u, except for amdoparvoviruses, is a phospholipase A2
(PLA2) enzyme domain, which enables viruses to escape from endosomal vesicles into the cytosol
during cell entry [20–26]. Other motifs in VP1u were found to be essential for the infection. In AAV
these motifs include signals that are known to be involved in protein interaction, endosomal sorting,
and signal transduction in eukaryotic cells [27]. In B19V, a receptor-binding domain (RBD) required
for virus uptake was identified at the N-terminal of the VP1u [28].
To infect the cell, parvoviruses follow an intricate path from the cell surface to the nucleus where
they deliver the viral DNA for replication. During the process of entry, the incoming parvovirus
capsids undergo a program of conformational rearrangements triggered by specific cellular factors that
facilitate their intracellular transport [29,30]. A major capsid rearrangement that is largely conserved
among parvoviruses involves the externalization of the VP1u region. Initially sequestered in mature
virions, VP1u and its essential motifs become accessible at the particle surface during entry triggered
by the acidic endosomal environment [10,16,31]. Besides low pH, AAVs may require additional cellular
factors [31]. An exception is B19V, whose VP1u becomes accessible during the initial interactions with
cellular receptors [32]. VP1u exposure occurs through the five-fold channel that connects with the
interior of the capsid [33–36]. Structural and in vitro studies suggest that these channels serve not only
as portals for the externalization of N-terminal capsid protein sequences but also for the packaging
and release of the viral genome [16,31,37–41]. Mutations that perturb the functional structure of the
channel result in defective genome encapsidation, uncoating and VP1u externalization [38,42,43].
B19V represents again an exception as the VP1u seems to be already exposed on the capsid surface,
although in a conformation that is not accessible to antibodies [44].
This review focuses on the VP1u of B19V, which shares common aspects with other parvoviruses
but has unique features, like its structural conformation relative to the virion, immunodominance,
extraordinary length or the presence of a receptor-binding domain responsible for the restricted tropism
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of the virus. We present the current knowledge on the different VP1u motifs, their functions in the
virus infection and the potential biotechnological applications of the B19V VP1u in human therapy
and diagnostics.
2. Human Erythroparvovirus B19 (B19V)
B19V is the most prominent and well-characterized human pathogen within the Parvoviridae
causing a mild childhood rash disease named erythema infectiosum or fifth disease [45]. The infection
is often asymptomatic; however, in adults, B19V infection may induce a wide range of more severe
pathological conditions, such as arthralgias and arthritis [46]. B19V infection may lead to aplastic
crisis in patients with pre-existing bone marrow disorders and shortened red cell survival [47] and
persistent infection in immunocompromised persons. Infection during pregnancy may result in
hydrops fetalis and fetal death [48]. B19V was the first parvovirus known to cause disease in humans [49].
Since 2005, other human parvoviruses have been identified and include human bocavirus (HBoV1-4),
parvovirus 4, bufavirus, tusavirus and cutavirus. Except for HBoV, which has been implicated in acute
respiratory tract infections [50], the rest are emergent human parvoviruses with uncertain clinical
significance [45,51].
B19V is transmitted via aerosol droplets that come into contact with the upper respiratory tract
mucosa [47]. The virus crosses the mucosal epithelium through a yet unknown mechanism and
disseminates with the bloodstream to the bone marrow, where it infects erythroid precursors at a
particular erythropoietin (EPO)-dependent stage of differentiation [52–54]. The extraordinary narrow
tropism of B19V is mediated at different levels of the viral life cycle. Crucial steps of the viral
infection, such as uptake, genome replication, transcription, splicing and packaging, are restricted
to the EPO-dependent erythroid differentiation around the proerythroblast stage [54–60]. The lytic
replication cycle results in the destruction of the erythroid precursor cells [61,62], which accounts for
the hematological syndromes observed during the infection [47]. Acute infection frequently results in
high-titer viremia, which precedes the onset of clinical manifestations and has been associated with
B19V transmission through transfusion and plasma-derived medicinal products [63].
3. B19V Capsid
The ssDNA genome of B19V is packaged into a small, nonenveloped, T = 1 icosahedral capsid.
Similar to the genome of dependoparvoviruses, the B19V genome has two identical inverted terminal
repeats (ITRs; ~383 nt), which serve as the origin of replication [64]. The capsid consists of 60 structural
subunits of two N-terminal VP variants, VP1 and VP2. Approximately 95% are VP2 (major VP;
60 kDa) and 5% are VP1 (minor VP; 86 kDa) [65]. VP1 and VP2 are generated through alternative
splicing, resulting in the same C-terminal sequence but VP1 contains 227 additional residues at the
VP1 N-terminal region, the so-called VP1 “unique region” (VP1u). The 60 protomers form 20 trimeric
capsomers in the cytoplasm of the infected cell, which are assembled to an icosahedral capsid structure
in the host nucleus. Due to the T = 1 symmetry, all protein subunits can be assembled in the same
orientation to each other. This perfect symmetry enables an optimal thermodynamic sink for each
protomer interaction, forming a very stable capsid around the ssDNA genome.
Large-scale propagation of native B19V is not possible due to the lack of a fully permissive cell
culture system. Accordingly, structural studies have been performed with recombinant B19V-like
particles, which are similar, although not identical, to infectious native capsids. The structure of the
VP2 recombinant particle has been determined to ~3.5 Å resolution [36]. Similar to other parvoviruses
and many icosahedral viruses, the major capsid protein VP2 is structured as a “jelly roll” with a
β-barrel motif. The loops connecting the strands of the β-barrel define the capsid surface topology that
differentiates B19V from other parvoviruses. B19V lacks the prominent protrusions at the icosahedral
threefold axes characteristic in other parvoviruses. The channel at the fivefold icosahedral axis is
surrounded by a large canyon-like depression. Different from other parvoviruses, the channel in B19
VP2 capsids is constricted at its outside end. However, a cluster of glycine residues at this position
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may confer sufficient flexibility to open the channel upon specific cellular triggers during the infection.
A striking difference between B19V and other parvoviruses is the external position of the N-VP2 and
probably also VP1u [36,66]. Accordingly, the role of the fivefold channel in B19V would be limited to
the externalization and packaging of the viral genome.
4. VP1u Is the Immunodominant Region of the Capsid but It Is Not Accessible in Native Virions
Although VP1u may occupy a surface position in the B19V capsid, different regions of the protein
were shown to be inaccessible to antibodies. However, exposure of native capsids to heat or low pH
rendered these regions accessible without capsid disassembly. In contrast to native virions, VP1u is
always accessible in recombinant B19V-like particles [44]. The inaccessibility of VP1u in native virions
is not well understood and may be explained by a compact structural conformation, or by the presence
of a masking structure hiding the essential protein domains to the immune system. Despite the
non-accessible conformation of VP1u in native particles, this protein is the immunodominant part of
the capsid and contains clusters of critical neutralizing epitopes [67,68] (Figure 1).
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Typically, neutralizing antibodies prevent the viral infection by interfering with early steps of the
viral life cycle, i.e., attachment to cellular receptors, uptake, fusion, or conformational changes required
for entry [69,70]. Importantly, the inhibition by neutralizing antibodies should be distinguished from
the opsonization of viruses by antibodies, which can hamper the viral infection by immobilization of
the virus and subsequent degradation of the immune complex by the complement system, immune
cells or also by the cytoplasmic TRIM21/proteasome mechanism [71]. However, the specific targeting
of essential capsid protein domains by neutralizing antibodies is required to efficiently interfere with
the viral infection. Upon B19 viremia, the humoral immune response first generates IgM antibodies,
which predominantly target the major capsid protein VP2. With the class-switch and long-term
immunity, an increasing percentage of B lymphocytes secrete neutralizing antibodies against the
VP1u region [72]. In this regard, a deficient immune response to VP1u has been associated with
persistent infections, emphasizing the important role of the immune response against VP1u in clearing
the virus [73,74].
Immunization experiments with vaccine candidates based on virus-like particles (VLPs)
demonstrated that VP1u is essential to raise a strong neutralizing response against B19V [75,76].
However, the neutralization mechanism of antibodies targeting VP1u has remained largely elusive.
Being the immunodominant region of the capsid, the originally inaccessible VP1u should become
exposed in the extracellular milieu, and not inside endosomes, as shown for other parvoviruses. In line
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with this assumption, it has been shown that a neutralizing antibody against the N-terminal part of
the VP1u was unable to bind native cell-free virions but was able to block virus entry into susceptible
cells. Moreover, capsids without VP1u were unable to internalize into susceptible cells, demonstrating
the involvement of the VP1u in B19V uptake [32,54]. These findings explain the high neutralization
potential of VP1u antibodies, which target exclusively capsids during the initial interaction with cell
receptors and block virus uptake, and further emphasize the importance of VP1u as an essential
component of prospective B19V vaccines.
5. Role of VP1u in the Restricted Tropism of B19V
B19V has a remarkable narrow tropism. The virus shows productive infection exclusively
in erythroid precursor cells at EPO-dependent intermediate erythroid differentiation stages,
with increasing permissiveness from BFU-E to erythroblasts [53]. Viral tropism can be determined
already at the cell surface by the expression of specific cell receptors required for virus entry and/or
intracellularly by receptor-independent post-entry replication steps. The marked erythroid tropism
of B19V is determined at multiple steps, i.e., the receptor-mediated uptake, genome replication,
transcription, splicing and packaging [56,57,77]. A virus requiring such strict intracellular conditions
for replication would also require a selective mechanism of cell entry to target exclusively the few cells
where the virus can replicate. This strategy would allow the virus to avoid internalizing non-permissive
cells, which would lead to abortive infections and inefficient viral propagation. Accordingly, it would
be expected that B19V uses an erythroid-specific surface molecule as an entry receptor.
5.1. VP1u Contains a Receptor-Binding Domain That Is Essential for Virus Entry into Permissive Cells
The neutral glycosphingolipid globoside (Gb4), also known as P antigen, has long been considered
the primary receptor of B19V [78]. A large body of evidence suggests that B19V recognizes Gb4 and
that the interaction is required for the infection [79–82]. However, the wide-range Gb4 expression does
not correlate well with B19V binding and uptake and cannot either explain the pathogenesis or the
remarkable narrow tissue tropism of the virus [83]. By using a knockout cell line, we demonstrated that
Gb4 does not have the expected function as the primary cell surface receptor required for B19V entry.
Instead, Gb4 has an essential role at a post-entry step after virus uptake and before the delivery of the
viral genome into the nucleus for replication [84]. Other receptor molecules, such as α5β1 integrin [85]
and Ku80 autoantigen [86] have been proposed as potential coreceptors for B19V infection. However,
the restricted uptake of B19V does not correspond with their wide expression profiles.
In an earlier study, we showed that the VP1u harbors a receptor-binding domain (RBD),
which enables the uptake of the virus. Purified recombinant VP1u (recVP1u) was able to bind
and to internalize exclusively into B19V permissive cells. Moreover, incorporation of VP1u subunits
on bacteriophage VLPs by chemical coupling enabled their internalization into B19V permissive
cells (Figure 2) [59]. The VP1u cognate receptor has not yet been identified, but its expression
profile corresponds with the restricted tropism of B19V, being expressed exclusively in cells at
erythropoietin-dependent erythroid differentiation stages [54,59].
5.2. Mapping and Structural Characterization of the Receptor-Binding Domain in the VP1u
The receptor-binding domain (RBD) in the VP1u was identified by using recVP1u variants with
increasing N- and C-terminal truncations. The VP1u variants internalized normally when they were
truncated less than 5 AA at the N-terminus or less than 147 AA at the C-terminus. Longer truncations at
both ends decreased or blocked VP1u uptake [28]. According to these results, the RBD spans the region
between AA 5–80 of VP1u, which explains the detectable exposure of this domain on the surface of
susceptible cells before uptake [32,87], as well as the presence of a cluster of neutralizing epitopes [67,68].
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The secondary structure analysis of the N-terminal of VP1u (AA 1–80) from natural B19V isolates,
predicted a cluster of three α-helices with high confidence: helix 1 (AA 14–31), helix 2 (35–45),
and helix 3 (59–68) (Figure 3A). However, only helix 1 was conserved among other erythroparvoviruses
(Figure 3B) and isplayed a prominent amphiphilic character. The marked segregation of polar and
hydrophobic amino acids between the two op osite flanks of th α-helix is well suited for receptor
binding. Compared with the residues of the hydrophilic side, the amino acids of the hydrophobic side
were highly conserved (Figure 3C). Point mutations on the hydrophobic side blocked VP1u binding
and internalization, suggesting a critical role of these residues in the interaction of VP1u with its
cognate cellular receptor [28].
Th sequence analysis of the first 80 amino acids of VP1u predicted two additional helices
(Figure 3A). Disruption of the tertiary conformation of these domains by the introduction of
flexible sequences strongly impaired VP1u internalization. This observation suggests that the
spatial configuration of the three helices is crucial for VP1u binding to its cognate receptor and
subsequent uptake. An ab initio modeling of the RBD by the QUARK algorithm [88] predicted a
helix-like spatial configuration of the three helices (Figure 4A,B), where a cluster of conserved and
internalization-relevant amino acids was modeled in close proximity (Figure 4C,D) [28]. The spatial
proximity of function-relevant residues may correspond to a critical receptor-interacting site.
5.3. VP1u Cognate Receptor Facilitates B19V Targeting and Uptake Exclusively into Permissive Cells
B19V requires a strict intracellular environment for replication that can only be found in the
erythroid progenitor cells (EPCs) in the bone marrow. The essential intracellular factors appear to
be simultaneously upregulated in EPCs during the EPO-dependent differentiation stages. A study
has shown that the internalization and the replication of B19V are considerably enhanced when
CD34+ hematopoietic stem cells were stimulated with EPO [57]. Not surprisingly, the two cell
lines that are most frequently used to study B19V infection, the megakaryocyte-erythroid UT7/Epo
cells [89] and the erythroleukemic KU812Ep6 cells [90], are both derived from an EPO-dependent
subclone. EPO signaling maintains the survival of cells that entered the intermediate erythroid
differentiation stages [91–93]. Besides EPO signaling, B19V infection requires hypoxic conditions,
which characterize the bone marrow microenvironment where the virus replicates. Hypoxia upregulates
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the signal transducer and activator of transcription 5 (STAT5) pathway, which facilitates viral DNA
replication [61,94,95]. During the EPO-dependent differentiation stages, a cluster of erythroid-specific
genes is upregulated [96], including the VP1u cognate receptor [59], which jointly are essential for
B19V replication. In this regard, the main role of the VP1u receptor would be to facilitate the targeting
and the uptake of B19V exclusively into cells providing a permissive intracellular environment for the
infection. This strategy prevents the internalization into non-permissive cells, which would result in
abortive infection.Viruses 2020, 12, x FOR PEER REVIEW 7 of 22 
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Figure 3. Structural motifs within the VP1u RBD. (A) Amino acid sequence of the N-terminal of VP1u
(AA 1–80) and the three predicted alpha helices (underlined red). (B) Conservation of alpha helix 1
among erythroparvoviruses. (C) Modeled helical wheel of the conserved helix 1 (AA 14–31) shows
the spatial arrangement of hydrophobic and polar amino acids within helix 1. Amino acid differences
found in B19V isolates are shown in a wider radius. Hydrophobic = orange; polar = green; basic = blue;
acid = red. The helical wheel of the simian parvovirus helix 1 is shown.
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Figure 4. Ab initio modeling of the RBD in the VP1u. ront and side views. Helix 1 appears in
blue (AA 14–31), helix 2 in yellow (AA 35–45), helix 3 in re ( A 57–68). (B) Helix distribution and
sequence of the modeled AA 14–68. The amino acids required for VP1u internalization are colored in
orange (hydrophobic) and green (polar). (C) The spatial distribution of essential amino acids is shown
as spheres in the helical structure (D) and in the surface model of the RBD.
5.4. Evolutionary Aspects of B19V Restricted Tropism and the Origin of the RBD in the VP1u
The origin of the marked tropism of B19V for erythroid precursors in the bone marrow is
not known. The erythroparvovirus and dependoparvovirus genomes sh w striking similarities,
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both having identical hairpin telomeres at both sides, and related replication mechanism [97]. It is
conceivable that the erythroparvovirus ancestor was dependent on helper virus co-infections. In line
with this hypothesis, several studies observed the enhancement of B19V replication and gene expression
in non-permissive cells in the presence of helper virus genes [98,99]. Besides the enhanced genome
replication, adenovirus genes transactivated the B19V promoters, including the p44 promoter in the
middle of the genome (nt 2247), which is normally silenced during B19V infection [100,101]. The p44
promoter is homologous to the promoters that initiate the expression of the structural capsid proteins in
other parvoviruses. Interestingly, the expression of the structural proteins represents a limiting factor in
B19V infection in non-erythroid cells. The transcription of the structural genes from the p44 promoter
might have played an important role in the helper-dependent ancestors of erythroparvoviruses
but could have been replaced during evolution by an alternative helper-independent replication in
erythroid cells. In contrast to most other parvoviruses, B19V shows alternative splicing in the transcript
from the p6 promoter that also enables the expression of the distal genes [102]. This exceptional splicing
mechanism of B19V, which strikingly occurs only in EPCs, makes the internal and helper-dependent
p44 promoter dispensable. Interestingly, there is another putative internal promoter (p55) at nt 2308
that might have similar properties.
According to this evolutionary model (Figure 5), the erythroparvovirus ancestor would have
generally exhibited a helper virus-dependent replication in different tissues, and sporadically,
a helper-independent replication in EPCs. However, without a specific targeting and internalization
into the erythroid progenitor cells, the overall infection still depended on the helper virus co-infection.
The erythroid-specific transcription of the structural genes from the p6 promoter generates a transcript
with a longer 5′-UTR that possibly allows the displacement of the start codon of the capsid proteins
and consequently, a longer VP1u region (Figure 6). The additional N-terminal amino acid sequence,
expressed only during the helper-independent infection in erythroid cells, might have evolved to
the RBD in the VP1u. The erythroid-specific targeting boosted the infection in the EPCs and thus
represented a positive feedback loop that promoted the autonomous replication in the erythroid
tissue. Vice versa, the helper-independent replication was the driving force for the positive feedback
mechanism. The positive feedback enhanced the reliance on additional erythroid-specific factors and
thus finally led to the extreme tropism of erythroparvoviruses.
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6. Role of VP1u in the Subcellular Trafficking of Incoming B19V
To infect the cell, parvoviruses follow a complex route from the plasma membrane to the nucleus
where they replicate. Various domains in the VP1u of parvoviruses have been shown to play a
critical role in the process by assisting the transport of the incoming capsids throughout the different
membrane-enclosed organelles and the highly crowded cytosol and by promoting their translocation
through the nuclear pore complex (NPC) into the nucleus (Figure 6).
6.1. The Phospholipase A2 (PLA2) Domain
Following the interaction of the VP1u RBD with its cognate receptor, B19V is internalized by
clathrin-mediated endocytosis and enters the endosomal pathway [104]. Endosomes provide cues that
trigger capsid conformational rearrangements required for subsequent trafficking steps and contribute
to the transport of incoming viruses to the nuclear vicinity. However, the mechanism followed by
parvoviruses to escape from endosomal vesicles into the cytosol remains unclear. Phospholipase A2
enzymes (PLA2s) catalyze the hydrolysis of phospholipids and the release of lipid mediator precursors.
Accordingly, PLA2s are key enzymes in many cellular processes such as lipid membrane metabolism,
inflammation, membrane remodeling, host defense, and signal transduction [105]. PLA2s are found
in mammalian tissues as well as in arachnids, insects, mollusks, reptiles, plants, and bacteria.
A PLA2 domain containing the typical catalytic motif HDXXY and the calcium-binding site GXG is
conserved in the VP1u of parvoviruses, including B19V (except for amdoparvoviruses) [21–23,25,106].
Mutations in either of these motifs disturbed both, the enzymatic activity and viral infectivity [20,21,23].
The pharmacological disruption of endosomal membranes or co-infection with endosomolytically
active adenovirus, but not with inactive variants, partially rescued the infectivity of the PLA2 mutants,
suggesting a role of the VP1u PLA2 in altering the endosomal membrane integrity to enable endosomal
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escape of viruses into the cytosol [24,26]. In B19V, VP1u mutations not related to the critical PLA2
motifs were also shown to reduce the enzymatic activity, probably by disrupting the three-dimensional
rearrangement surrounding the PLA2 domain [107]. Although the PLA2 may facilitate the endosomal
escape of incoming B19V, the mechanism involved is poorly understood. Interestingly, B19V endosomal
escape was shown to occur without detectable endosomal membrane permeabilization or damage [104]
and the enzymatic requirements for the PLA2 activity, i.e., pH and calcium concentration are not
optimal in the endocytic compartment [106]. Accordingly, it remains unclear how the PLA2 activity of
VP1u supports the escape of the endosomal capsids.
B19V PLA2 has been shown to up-regulate Ca2+ entry [108], to inhibit Na+/K+ ATPase activity
and K+ channels [109,110], and to up-regulate ENaC [111]. These activities may contribute to the
pathophysiology of B19V infections. Moreover, due to the inflammatory-like effects exerted by
recombinant VP1u in cultured fibroblast [112] and in UT7/Epo cells [107], it has been hypothesized
that the PLA2 domain of VP1u may contribute to B19V-associated syndromes, such as arthropathy
and autoimmunity.
6.2. Nuclear Localization Signals (NLSs)
Following endosomal escape, parvovirus capsids are imported into the nucleus. Nuclear import
of most proteins involves classical nuclear localization signals (NLSs) consisting of a stretch of basic
amino acids, which interact with importin-α/importin-β to mediate transport through the nuclear
pore [113]. The size of the parvovirus capsid is below the diameter limit of the nuclear pore complex
(NPC). Therefore, capsids can theoretically be translocated through the NPC intact or without major
disassembly [114]. NLSs have been identified in the VP1u from several parvoviruses [12–19] and confer
nuclear import potential to the incoming particles via interaction with importin-β [115]. The VP1u of
B19V does not display a motif resembling a classical NLS, however, when expressed in eukaryotic cells,
VP1u accumulates in the cytoplasm and in the nucleus [107]. The stretch of basic amino acids found in
VP2 occupies an internal position in the capsid and has been implicated in the nuclear translocation
of assembly intermediates [116]. Accordingly, the mechanism of nuclear import of B19V remains
uncertain and might differ fundamentally from that of other parvoviruses.
7. Biotechnological Applications of the VP1u of B19V
Nanocarriers are designed to efficiently deliver therapeutic molecules to specific tissues minimizing
adverse effects [117]. Despite important progress, the drug delivery technology based on synthetic
nanocarriers remains highly inefficient. One meta-analysis revealed that over 99% of the drugs do
not reach the diseased cells and accumulate instead in non-target tissues or are cleared from the
body [118]. Ideally, nanocarriers must specifically internalize into the target cells, escape from the
endocytic compartment, and release their payload into the cytosol. These processes resemble the early
infection steps of viruses, which operate as powerful natural nanocarriers to efficiently deliver genetic
material into target cells by complex mechanisms shaped by evolution. The targeting machinery that
is engaged in the early viral infection steps can be utilized to generate virus-inspired nanocarriers as
efficient drug or gene delivery vehicles [119,120]. In this regard, the VP1u of B19V includes many
interesting features that can potentially be exploited for drug delivery and diagnostics, i.e., specific cell
targeting, efficient cell entry, and endosomal escape.
7.1. Specific Biomarker for EPO-Dependent Erythroid Differentiation Stages
Diverse hematological conditions (e.g., leukemia, thalassemic and myelodysplastic syndromes,
bone marrow metastases of solid tumors, septicemia, or severe health conditions after surgery)
are typically associated with the presence of erythroblasts outside the bone marrow [121–126].
Accordingly, the screening of peripheral blood for nucleated red blood cells (NRBCs) is used to
recognize hematological disorders or severe health conditions. Assays to detect NRBCs must be
very sensitive because the presence of only a few NRBCs can indicate serious underlying disorders.
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Unfortunately, automated hematology analyzers may not detect low levels of NRBCs. Besides,
they generate suspect flags, which should be examined manually [127]. The currently used automated
detection of NRBCs in peripheral blood has a detection limit of 1-2 erythroblasts per 100 white
blood cells [123,128]. In comparison, VP1u decorated MS2 capsids were able to detect as few as
one erythroleukemic UT7/Epo cell in 100,000 isolated white blood cells (unpublished observations).
The sensitive identification of erythroblasts in the peripheral blood by fluorescent VP1u bioconjugates
has the potential to improve the detection of diverse hematological disorders or severe health conditions
and to facilitate an early diagnosis without the systematic need of an invasive technique such as bone
marrow biopsy.
The precise identification and isolation of erythroid progenitor cells is important in hematological
research and in diagnostics to characterize and treat bone marrow disorders. However, the technique
remains rather complex and laborious, since the currently used markers are not lineage-specific (CD36,
CD38, CD44, CD45, CD71, CD105, EPOR) or are broadly expressed during the erythroid development
(glycophorin A). Therefore, the combination of several antibodies is necessary to achieve the correct
identification [124,129–134]. In contrast, the fluorescent VP1u bioconjugate appeared as a unique and
highly sensitive marker for the EPO-dependent erythroid differentiation stages and readily detected
these cells in heterogeneous cell populations from different tissues [54]. The findings show the potential
of the VP1u as a biomarker to identify and sort erythroid differentiation stages in a simpler procedure
than it has been practiced so far.
It is expected that the future biotechnological applications of the VP1u will be spurred by the
identification of its cognate receptor. However, the identity of the VP1u receptor will not necessarily
be determinant for the applicability of the VP1u as a specific cellular marker. Historically, it is not
uncommon to use cell surface markers to identify cell populations based on empirical evidence without
knowing the identity and/or the function of the targeted receptors.
7.2. Specific Drug Delivery and Chemotherapy
7.2.1. β-Hemoglobin Disorders
β-hemoglobin disorders are a group of highly prevalent hereditary diseases caused by mutations
in the gene encoding for the β-chain of hemoglobin, resulting in qualitative and quantitative defects in
β-globin production. β-thalassemias are a heterogeneous group of genetic disorders characterized by
the partial or complete absence of β-globin chain production, leading to anemia and iron overload.
The disease is highly prevalent with 80–90 million carriers worldwide. Without diagnosis and
appropriate treatment, the severe forms of β-thalassemia lead to death before age 20 [135]. Sickle cell
disease (SCD) is the most common and severe hemoglobinopathy. In SCD, a single mutation in the
β-globin gene results in the production of an aberrant hemoglobin molecule, which causes the rigid
sickle-like shape of erythrocytes. Without treatment, SCD is lethal before age five [136].
Patients with severe β-hemoglobin disorders require regular blood transfusions, which lead to iron
overload and related complications. Accordingly, iron chelation therapies are also required [137,138].
The most severe forms of the disease have been successfully treated by allogeneic hematopoietic stem
cell transplantation from a matched related donor. However, major drawbacks are the difficulty to
find a histocompatible donor and the need for extensive immunosuppressive regimens, with the
risk of immunological complication. Besides, this approach is not accessible for many affected
individuals [139,140]. Gene therapy and gene editing strategies to restore the globin genes have
generated promising results. However, these approaches lack cell-specific vectors, resulting in poor
efficiency and the risk of insertional oncogenesis [141–143].
Due to the numerous drawbacks associated with the current therapeutic strategies, there is a great
interest in developing novel therapeutic options. The therapeutic targeting of RNA by double-stranded
RNA-mediated interference (RNAi) or by antisense oligonucleotides (ASOs) allows specific inhibition
of the target of interest and a very rapid transferability to the clinics [144]. However, the delivery of
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nucleic acid molecules to the bone marrow remains highly inefficient. The MS2 capsid is a well-studied
vector for drug delivery and can be easily loaded with therapeutic ASOs or small interfering RNAs
(siRNA) [145,146]. This strategy provides protection of the therapeutic nucleic acid molecules in
the extracellular milieu, avoids solubility problems, and thus allows more the options to improve
the modifications of the oligonucleotides. In a previous study, we showed that anchoring of VP1u
subunits to the surface of MS2 capsids retargets the particles to erythroid cells. This finding offers
the opportunity to deliver encapsidated genetic material specifically to this cell population [59].
Potential targets of therapeutic ASOs or siRNA might be different factors involved in the regulation of
erythropoiesis, such as transferrin receptor 2, or regulatory elements of fetal hemoglobin, such as B-cell
lymphoma/leukemia 11A and erythroid Kruppel-like factor. Specific downregulation of such factors in
erythroid progenitor cells would significantly alleviate symptoms of β-hemoglobin disorders [147–150].
7.2.2. Erythroleukemia
Acute erythroleukemia is a rare disorder associated with a poor prognosis. A study reported
a median overall survival of 8 months [151]. The treatment of erythroleukemia is compromised
due to the systemic distribution and resistance of the malignant cells to chemotherapeutics [152,153].
Therefore, the successful elimination of erythroleukemic cells by a cytotoxin requires a “magic bullet”
strategy—an efficient and specific targeting of the toxin to cancer cells—minimizing adverse effects
to the surrounding healthy cells [154]. Erythroleukemias exhibit proliferating cancer cells in the
early and intermediate erythroid differentiation stages [155], which are the target cells of the VP1u.
Accordingly, the VP1u-mediated toxin delivery represents a possible strategy to overcome the resistance
of erythroleukemia to chemotherapeutics. In previous studies, VP1u successfully targeted a toxin
specifically to malignant erythroid precursors and thus selectively eliminated these cells from a mixed
cell culture [156].
The immunity of many individuals against B19V would represent a serious obstacle for the
application of the VP1u-targeted delivery. About half of the human population is seropositive for
anti-B19V antibodies. Similar problems are faced in the application of AAV vectors for gene therapy,
where many individuals have antibodies against serotypes 2 and 3 [157]. Following the natural
mechanism of viruses to evade the immune system, the AAV researchers are searching for AAV isolates
and isotypes, which are not neutralized by the common pool of antibodies, but still offer the beneficial
properties of the original virus [158–160]. In the case of a short protein with a single function as with
the RBD of the VP1u, an immune escape by antigenic drift is easier to achieve without disturbing the
receptor binding and internalization capacity. The natural mutations observed in various B19V isolates
(Figure 3C) together with the mutational studies already performed [28], provide an excellent basis to
mimic an antigenic drift of the VP1u RBD without decreasing the targeting function of the protein.
Furthermore, there exist different options to reduce the antigenicity of a therapeutic protein, such as
a fusion with an abundant endogenous protein as serum albumin or the immunoglobulin constant
fragments [161–163]. The coupling to these endogenous proteins does not only circumvent the immune
response, but also considerably increases the solubility, stability, and serum half-life of the therapeutic
proteins. In line with this concept, bovine serum albumin (BSA) was used as an adaptor molecule for
the attachment of the toxins to a VP1u-NeutrAvidin complex. The results showed that the modified
BSA remained soluble after the attachment of 20–30 fluorescein or toxin molecules to the protein and
was targeted exclusively to VP1u-expressing cells. The stability of the drug attachment might be
increased by packing the effector molecule into a capsid, as shown with the MS2 bacteriophage in
previous studies [145,146,164]. The specific delivery of an encapsidated effector allows a higher dose
per delivered particle without increasing toxicity. Besides, the capsid can be engineered to incorporate
multiple residues to improve the targeting efficiency.
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8. Concluding Remarks
The VP1u is a key component of the capsid of human parvovirus B19 with essential functions
in multiple steps of the infection, such as tissue tropism, uptake, intracellular trafficking, and entry.
The VP1u is also the immunodominant region of the capsid and a crucial component for prospective
vaccines. In the future, efforts will be focused to better understand the essential functions of VP1u in
B19V infection and to identify the VP1u interactome, notably its cognate cell receptor.
Recent innovations in protein engineering and nanomaterials science have the potential to
revolutionize the conventional methods of diagnosis and treatment, bringing new hopes to patients.
However, to date, a major barrier in their clinical application remains their poor selective targeting.
Only a few clinically approved nanoscale delivery vehicles integrate molecules to selectively target
the cargo to the tissue of interest. In this regard, the remarkable erythroid specificity of the VP1u
offers novel opportunities to generate virus-inspired biomarkers and nanocarriers to specifically target
erythroid cells. This approach may contribute to a better understanding of the mechanisms governing
erythroid development and to treat disorders of the erythroid lineage. Efforts to circumvent the
VP1u immune response and to optimize the stability and density of cargo delivery will facilitate its
transferability to human diagnostics and therapies.
Author Contributions: Conceptualization, R.L. and C.R.; writing—original draft preparation, C.R.; review and
editing, R.L., J.B. and C.R.; Supervision, funding acquisition, C.R. All authors have read and agreed to the
published version of the manuscript.
Funding: This work was supported by the Swiss National Science Foundation (grant number 31003A_179384)
to J.B.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Cotmore, S.F.; Tattersall, P. Parvoviruses: Small does not mean simple. Annu. Rev. Virol. 2014, 1, 517–537.
[CrossRef] [PubMed]
2. Kailasan, S.; Agbandje-Mckenna, M.; Parrish, C.R. Parvovirus Family Conundrum: What Makes a Killer?
Annu. Rev. Virol. 2015, 2, 425–450. [CrossRef] [PubMed]
3. François, S.; Filloux, D.; Roumagnac, P.; Bigot, D.; Gayral, P.; Martin, D.P.; Froissart, R.; Ogliastro, M.
Discovery of parvovirus-related sequences in an unexpected broad range of animals. Sci. Rep. 2016, 6, 1–13.
[CrossRef] [PubMed]
4. Cotmore, S.F.; Agbandje-McKenna, M.; Canuti, M.; Chiorini, J.A.; Eis-Hubinger, A.M.; Hughes, J.; Mietzsch, M.;
Modha, S.; Ogliastro, M.; Pénzes, J.J.; et al. ICTV virus taxonomy profile: Parvoviridae. J. Gen. Virol. 2019,
100, 367–368. [CrossRef] [PubMed]
5. Samulski, R.J.; Muzyczka, N. AAV-mediated gene therapy for research and therapeutic purposes.
Annu. Rev. Virol. 2014, 1, 427–451. [CrossRef] [PubMed]
6. Cotmore, S.F.; Tattersall, P. Characterization and molecular cloning of a human parvovirus genome. Science
1984, 226, 1161–1165. [CrossRef]
7. Cotmore, S.F.; Tattersall, P. DNA replication in the autonomous parvoviruses. Semin. Virol. 1995, 6, 271–281.
[CrossRef]
8. Tattersall, P.; Cawte, P.J.; Shatkin, A.J.; Ward, D.C. Three structural polypeptides coded for by minite virus of
mice, a parvovirus. J. Virol. 1976, 20, 273–289. [CrossRef]
9. Becerra, S.P.; Koczot, F.; Fabisch, P.; Rose, J.A. Synthesis of adeno-associated virus structural proteins
requires both alternative mRNA splicing and alternative initiations from a single transcript. J. Virol. 1988,
62, 2745–2754. [CrossRef]
10. Mani, B.; Baltzer, C.; Valle, N.; Almendral, J.M.; Kempf, C.; Ros, C. Low pH-dependent endosomal processing
of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal
sequence (N-VP1), N-VP2 cleavage, and uncoating of the full-length genome. J. Virol. 2006, 80, 1015–1024.
[CrossRef]
Viruses 2020, 12, 1463 14 of 21
11. Mietzsch, M.; Pénzes, J.J.; Agbandje-Mckenna, M. Twenty-five years of structural parvovirology. Viruses
2019, 11, 362. [CrossRef] [PubMed]
12. Vihinen-Ranta, M.; Kakkola, L.; Kalela, A.; Vilja, P.; Vuento, M. Characterization of a nuclear localization
signal of canine parvovirus capsid proteins. Eur. J. Biochem. 1997, 250, 389–394. [CrossRef] [PubMed]
13. Lombardo, E.; Ramírez, J.C.; Garcia, J.; Almendral, J.M. Complementary Roles of Multiple Nuclear Targeting
Signals in the Capsid Proteins of the Parvovirus Minute Virus of Mice during Assembly and Onset of
Infection. J. Virol. 2002, 76, 7049–7059. [CrossRef] [PubMed]
14. Vihinen-Ranta, M.; Wang, D.; Weichert, W.S.; Parrish, C.R. The VP1 N-Terminal Sequence of Canine
Parvovirus Affects Nuclear Transport of Capsids and Efficient Cell Infection. J. Virol. 2002, 76, 1884–1891.
[CrossRef] [PubMed]
15. Grieger, J.C.; Snowdy, S.; Samulski, R.J. Separate Basic Region Motifs within the Adeno-Associated Virus
Capsid Proteins Are Essential for Infectivity and Assembly. J. Virol. 2006, 80, 5199–5210. [CrossRef] [PubMed]
16. Sonntag, F.; Bleker, S.; Leuchs, B.; Fischer, R.; Kleinschmidt, J.A. Adeno-Associated Virus Type 2 Capsids
with Externalized VP1/VP2 Trafficking Domains Are Generated prior to Passage through the Cytoplasm and
Are Maintained until Uncoating Occurs in the Nucleus. J. Virol. 2006, 80, 11040–11054. [CrossRef] [PubMed]
17. Li, Q.; Zhang, Z.; Zheng, Z.; Ke, X.; Luo, H.; Hu, Q.; Wang, H. Identification and characterization of complex
dual nuclear localization signals in human bocavirus NP1. J. Gen. Virol. 2013, 94, 1335–1342. [CrossRef]
18. Boisvert, M.; Bouchard-Levesque, V.; Fernandes, S.; Tijssen, P. Classic Nuclear Localization Signals and a
Novel Nuclear Localization Motif Are Required for Nuclear Transport of Porcine Parvovirus Capsid Proteins.
J. Virol. 2014, 88, 11748–11759. [CrossRef]
19. Liu, P.; Chen, S.; Wang, M.; Cheng, A. The role of nuclear localization signal in parvovirus life cycle. Virol. J.
2017, 14, 17–22. [CrossRef]
20. Li, Y.; Zádori, Z.; Bando, H.; Dubuc, R.; Fédière, G.; Szelei, J.; Tijssen, P. Genome organization of the densovirus
from Bombyx mori (BmDNV-1) and enzyme activity of its capsid. J. Gen. Virol. 2001, 82, 2821–2825. [CrossRef]
21. Zádori, Z.; Szelei, J.; Lacoste, M.C.; Li, Y.; Gariépy, S.; Raymond, P.; Allaire, M.; Nabi, I.R.; Tijssen, P. A Viral
Phospholipase A2 Is Required for Parvovirus Infectivity. Dev. Cell 2001, 1, 291–302. [CrossRef]
22. Dorsch, S.; Liebisch, G.; Kaufmann, B.; von Landenberg, P.; Hoffmann, J.H.; Drobnik, W.; Modrow, S.
The VP1 Unique Region of Parvovirus B19 and Its Constituent Phospholipase A2-Like Activity. J. Virol. 2002,
76, 2014–2018. [CrossRef] [PubMed]
23. Girod, A.; Wobus, C.E.; Zádori, Z.; Ried, M.; Leike, K.; Tijssen, P.; Kleinschmidt, J.A.; Hallek, M. The VP1
capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus
infectivity. J. Gen. Virol. 2002, 83, 973–978. [CrossRef] [PubMed]
24. Farr, G.A.; Zhang, L.G.; Tattersall, P. Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach
the endosomal membrane during cell entry. Proc. Natl. Acad. Sci. USA 2005, 102, 17148–17153. [CrossRef]
[PubMed]
25. Qu, X.W.; Liu, W.P.; Qi, Z.Y.; Duan, Z.J.; Zheng, L.S.; Kuang, Z.Z.; Zhang, W.J.; Hou, Y. De Phospholipase
A2-like activity of human bocavirus VP1 unique region. Biochem. Biophys. Res. Commun. 2008, 365, 158–163.
[CrossRef] [PubMed]
26. Stahnke, S.; Lux, K.; Uhrig, S.; Kreppel, F.; Hösel, M.; Coutelle, O.; Ogris, M.; Hallek, M.; Büning, H. Intrinsic
phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles.
Virology 2011, 409, 77–83. [CrossRef]
27. Popa-Wagner, R.; Porwal, M.; Kann, M.; Reuss, M.; Weimer, M.; Florin, L.; Kleinschmidt, J.A. Impact of
VP1-Specific Protein Sequence Motifs on Adeno-Associated Virus Type 2 Intracellular Trafficking and Nuclear
Entry. J. Virol. 2012, 86, 9163–9174. [CrossRef]
28. Leisi, R.; Di Tommaso, C.; Kempf, C.; Ros, C. The receptor-binding domain in the VP1u region of parvovirus
B19. Viruses 2016, 8, 61. [CrossRef]
29. Harbison, C.E.; Chiorini, J.A.; Parrish, C.R. The parvovirus capsid odyssey: From the cell surface to the
nucleus. Trends Microbiol. 2008, 16, 208–214. [CrossRef]
30. Ros, C.; Bayat, N.; Wolfisberg, R.; Almendral, J.M. Protoparvovirus cell entry. Viruses 2017, 9, 313. [CrossRef]
31. Kronenberg, S.; Böttcher, B.; von der Lieth, C.W.; Bleker, S.; Kleinschmidt, J.A. A Conformational Change in
the Adeno-Associated Virus Type 2 Capsid Leads to the Exposure of Hidden VP1 N Termini. J. Virol. 2005,
79, 5296–5303. [CrossRef] [PubMed]
Viruses 2020, 12, 1463 15 of 21
32. Bönsch, C.; Zuercher, C.; Lieby, P.; Kempf, C.; Ros, C. The Globoside Receptor Triggers Structural Changes
in the B19 Virus Capsid That Facilitate Virus Internalization. J. Virol. 2010, 84, 11737–11746. [CrossRef]
[PubMed]
33. Tsao, J.; Chapman, M.S.; Agbandje, M.; Keller, W.; Smith, K.; Wu, H.; Luo, M.; Smith, T.J.; Rossmann, M.G.;
Compans, R.W.; et al. The three-dimensional structure of canine parvovirus and its functional implications.
Science 1991, 251, 1456–1464. [CrossRef] [PubMed]
34. Chapman, M.S.; Rossmann, M.G. Structure, sequence, and function correlations among parvoviruses.
Virology 1993, 194, 491–508. [CrossRef]
35. Llamas-Saiz, A.L.; Agbandje-McKenna, M.; Wikoff, W.R.; Bratton, J.; Tattersall, P.; Rossmann, M.G. Structure
determination of minute virus of mice. Acta Crystallogr. Sect. D Biol. Crystallogr. 1997, 53, 93–102. [CrossRef]
[PubMed]
36. Kaufmann, B.; Simpson, A.A.; Rossmann, M.G. The structure of human parvovirus B19. Proc. Natl. Acad.
Sci. USA 2004, 101, 11628–11633. [CrossRef]
37. Agbandje-McKenna, M.; Llamas-Saiz, A.L.; Wang, F.; Tattersall, P.; Rossmann, M.G. Functional implications
of the structure of the murine parvovirus, minute virus of mice. Structure 1998, 6, 1369–1381. [CrossRef]
38. Bleker, S.; Sonntag, F.; Kleinschmidt, J.A. Mutational Analysis of Narrow Pores at the Fivefold Symmetry
Axes of Adeno-Associated Virus Type 2 Capsids Reveals a Dual Role in Genome Packaging and Activation
of Phospholipase A2 Activity. J. Virol. 2005, 79, 2528–2540. [CrossRef]
39. Farr, G.A.; Cotmore, S.F.; Tattersall, P. VP2 Cleavage and the Leucine Ring at the Base of the Fivefold Cylinder
Control pH-Dependent Externalization of both the VP1 N Terminus and the Genome of Minute Virus of
Mice. J. Virol. 2006, 80, 161–171. [CrossRef]
40. Plevka, P.; Hafenstein, S.; Li, L.; D’Abrgamo, A.; Cotmore, S.F.; Rossmann, M.G.; Tattersall, P. Structure of a
Packaging-Defective Mutant of Minute Virus of Mice Indicates that the Genome Is Packaged via a Pore at a
5-Fold Axis. J. Virol. 2011, 85, 4822–4827. [CrossRef]
41. Castellanos, M.; Pérez, R.; Rodríguez-Huete, A.; Grueso, E.; Almendral, J.M.; Mateu, M.G. A slender tract of
glycine residues is required for translocation of the VP2 protein N-terminal domain through the parvovirus
MVM capsid channel to initiate infection. Biochem. J. 2013, 455, 87–94. [CrossRef] [PubMed]
42. Farr, G.A.; Tattersall, P. A conserved leucine that constricts the pore through the capsid fivefold cylinder
plays a central role in parvoviral infection. Virology 2004, 323, 243–256. [CrossRef] [PubMed]
43. Cotmore, S.F.; Tattersall, P. Mutations at the Base of the Icosahedral Five-Fold Cylinders of Minute Virus
of Mice Induce 3′-to-5′ Genome Uncoating and Critically Impair Entry Functions. J. Virol. 2012, 86, 69–80.
[CrossRef] [PubMed]
44. Ros, C.; Gerber, M.; Kempf, C. Conformational changes in the VP1-unique region of native human parvovirus
B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J. Virol.
2006, 80, 12017–12024. [CrossRef] [PubMed]
45. Qiu, J.; Söderlund-Venermo, M.; Young, N.S. Human Parvoviruses. Clin. Microbiol. Rev. 2017, 30, 43–113.
[CrossRef] [PubMed]
46. Vassilopoulos, D.; Calabrese, L.H. Virally associated arthritis 2008: Clinical, epidemiologic,
and pathophysiologic considerations. Arthritis Res. Ther. 2008, 10, 1–8. [CrossRef]
47. Heegaard, E.D.; Brown, K.E. Human Parvovirus B19. Clin. Microbiol. Rev. 2002, 15, 485–505. [CrossRef]
48. Bonvicini, F.; Bua, G.; Gallinella, G. Parvovirus B19 infection in pregnancy—Awareness and opportunities.
Curr. Opin. Virol. 2017, 27, 8–14. [CrossRef]
49. Cossart, Y.E.; Cant, B.; Field, A.M.; Widdows, D. Parvovirus-Like Particles in Human Sera. Lancet 1975,
305, 72–73. [CrossRef]
50. Christensen, A.; Kesti, O.; Elenius, V.; Eskola, A.L.; Døllner, H.; Altunbulakli, C.; Akdis, C.A.;
Söderlund-Venermo, M.; Jartti, T. Human bocaviruses and paediatric infections. Lancet Child Adolesc. Health
2019, 3, 418–426. [CrossRef]
51. Söderlund-Venermo, M. Emerging Human Parvoviruses: The Rocky Road to Fame. Annu. Rev. Virol. 2019,
6, 71–91. [CrossRef] [PubMed]
52. Ozawa, K.; Kurtzman, G.; Young, N. Replication of the B19 parvovirus in human bone marrow cell cultures.
Science 1986, 233, 883–886. [CrossRef] [PubMed]
53. Takahashi, T.; Ozawa, K.; Takahashi, K.; Asano, S.; Takaku, F. Susceptibility of human erythropoietic cells to
B19 parvovirus in vitro increases with differentiation. Blood 1990, 75, 603–610. [CrossRef] [PubMed]
Viruses 2020, 12, 1463 16 of 21
54. Leisi, R.; Ruprecht, N.; Kempf, C.; Ros, C. Parvovirus B19 uptake is a highly selective process controlled by
VP1u, a novel determinant of viral tropism. J. Virol. 2013, 87, 13161–13167. [CrossRef]
55. Guan, W.; Cheng, F.; Yoto, Y.; Kleiboeker, S.; Wong, S.; Zhi, N.; Pintel, D.J.; Qiu, J. Block to the Production
of Full-Length B19 Virus Transcripts by Internal Polyadenylation Is Overcome by Replication of the Viral
Genome. J. Virol. 2008, 82, 9951–9963. [CrossRef]
56. Wong, S.; Zhi, N.; Filippone, C.; Keyvanfar, K.; Kajigaya, S.; Brown, K.E.; Young, N.S. Ex Vivo-Generated
CD36+ Erythroid Progenitors Are Highly Permissive to Human Parvovirus B19 Replication. J. Virol. 2008,
82, 2470–2476. [CrossRef]
57. Chen, A.Y.; Guan, W.; Lou, S.; Liu, Z.; Kleiboeker, S.; Qiu, J. Role of Erythropoietin Receptor Signaling in
Parvovirus B19 Replication in Human Erythroid Progenitor Cells. J. Virol. 2010, 84, 12385–12396. [CrossRef]
58. Wolfisberg, R.; Ruprecht, N.; Kempf, C.; Ros, C. Impaired genome encapsidation restricts the in vitro
propagation of human parvovirus B19. J. Virol. Methods 2013, 193, 215–225. [CrossRef]
59. Leisi, R.; Nordheim, M.V.; Ros, C.; Kempf, C. The VP1u receptor restricts parvovirus B19 uptake to permissive
erythroid cells. Viruses 2016, 8, 265. [CrossRef]
60. Gallinella, G.; Manaresi, E.; Zuffi, E.; Venturoli, S.; Bonsi, L.; Bagnara, G.P.; Musiani, M.; Zerbini, M. Different
patterns of restriction to B19 parvovirus replication in human blast cell lines. Virology 2000, 278, 361–367.
[CrossRef]
61. Ganaie, S.S.; Qiu, J. Recent advances in replication and infection of human parvovirus B19. Front. Cell.
Infect. Microbiol. 2018, 8, 1–12. [CrossRef] [PubMed]
62. Luo, Y.; Qiu, J. Human parvovirus B19: A mechanistic overview of infection and DNA replication. Future Virol.
2015, 10, 155–167. [CrossRef] [PubMed]
63. Stramer, S.L.; Dodd, R.Y. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and
progress. Transfusion 2013, 53, 2375–2383. [CrossRef] [PubMed]
64. Deiss, V.; Tratschin, J.D.; Weitz, M.; Siegl, G. Cloning of the human parvovirus B19 genome and structural
analysis of its palindromic termini. Virology 1990, 175, 247–254. [CrossRef]
65. Cotmore, S.F.; McKie, V.C.; Anderson, L.J.; Astell, C.R.; Tattersall, P. Identification of the major structural
and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic
expression of isolated genomic fragments. J. Virol. 1986, 60, 548–557. [CrossRef] [PubMed]
66. Kaufmann, B.; Chipman, P.R.; Kostyuchenko, V.A.; Modrow, S.; Rossmann, M.G. Visualization of the
Externalized VP2 N Termini of Infectious Human Parvovirus B19. J. Virol. 2008, 82, 7306–7312. [CrossRef]
67. Saikawa, T.; Anderson, S.; Momoeda, M.; Kajigaya, S.; Young, N.S. Neutralizing linear epitopes of B19
parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J. Virol. 1993, 67, 3004–3009. [CrossRef]
68. Anderson, S.; Momoeda, M.; Kawase, M.; Kajigaya, S.; Young, N.S. Peptides derived from the unique region
of B19 parvovirus minor capsid protein elicitneutralizing antibodies in rabbits. Virology 1995, 206, 626–632.
[CrossRef]
69. Klasse, P.J.; Sattentau, Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses.
J. Gen. Virol. 2002, 83, 2091–2108. [CrossRef]
70. Klasse, P.J. Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv. Biol.
2014, 2014, 157895. [CrossRef]
71. Burton, D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2002, 2, 706–713. [CrossRef] [PubMed]
72. Modrow, S.; Dorsch, S. Antibody responses in parvovirus B19 infected patients. Pathol. Biol. 2002, 50, 326–331.
[CrossRef]
73. Kurtzman, G.J.; Cohen, B.J.; Field, A.M.; Oseas, R.; Blaese, R.M.; Young, N.S. Immune response to B19
parvovirus and an antibody defect in persistent viral infection. J. Clin. Investig. 1989, 84, 1114–1123.
[CrossRef] [PubMed]
74. Kurtzman, G.; Frickhofen, N.; Kimball, J.; Jenkins, D.W.; Nienhuis, A.W.; Young, N.S. Pure Red-Cell Aplasia
of 10 Years’ Duration Due to Persistent Parvovirus B19 Infection and Its Cure with Immunoglobulin Therapy.
N. Engl. J. Med. 1989, 321, 519–523. [CrossRef] [PubMed]
75. Bernstein, D.I.; El Sahly, H.M.; Keitel, W.A.; Wolff, M.; Simone, G.; Segawa, C.; Wong, S.; Shelly, D.; Young, N.S.;
Dempsey, W. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011, 29, 7357–7363.
[CrossRef]
Viruses 2020, 12, 1463 17 of 21
76. Chandramouli, S.; Medina-Selby, A.; Coit, D.; Schaefer, M.; Spencer, T.; Brito, L.A.; Zhang, P.; Otten, G.;
Mandl, C.W.; Mason, P.W.; et al. Generation of a parvovirus B19 vaccine candidate. Vaccine 2013, 31, 3872–3878.
[CrossRef]
77. Bua, G.; Manaresi, E.; Bonvicini, F.; Gallinella, G. Parvovirus B19 Replication and Expression in Differentiating
Erythroid Progenitor Cells. PLoS ONE 2016, 11, 1–19. [CrossRef]
78. Brown, K.E.; Anderson, S.M.; Young, N.S. Erythrocyte P antigen: Cellular receptor for B19 parvovirus.
Science 1993, 262, 114–117. [CrossRef]
79. Brown, K.E.; Cohen, B.J. Haemagglutination by parvovirus B19. J. Gen. Virol. 1992, 73, 2147–2149. [CrossRef]
80. Brown, K.E.; Hibbs, J.R.; Gallinella, G.; Anderson, S.M.; Lehman, E.D.; McCarthy, P.; Young, N.S. Resistance
to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N. Engl. J. Med. 1994,
330, 1192–1196. [CrossRef]
81. Chipman, P.R.; Agbandje-Mckenna, M.; Kajigaya, S.; Brown, K.E.; Young, N.S.; Baker, T.S.; Rossmann, M.G.
Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular
receptor. Proc. Natl. Acad. Sci. USA 1996, 93, 7502–7506. [CrossRef] [PubMed]
82. Nasir, W.; Nilsson, J.; Olofsson, S.; Bally, M.; Rydell, G.E. Parvovirus B19 VLP recognizes globoside in
supported lipid bilayers. Virology 2014, 456–457, 364–369. [CrossRef] [PubMed]
83. Weigel-Kelley, K.A.; Yoder, M.C.; Srivastava, A. Recombinant Human Parvovirus B19 Vectors: Erythrocyte P
Antigen Is Necessary but Not Sufficient for Successful Transduction of Human Hematopoietic Cells. J. Virol.
2001, 75, 4110–4116. [CrossRef] [PubMed]
84. Bieri, J.; Ros, C. Globoside Is Dispensable for Parvovirus B19 Entry but Essential at a Postentry Step for
Productive Infection. J. Virol. 2019, 93, 1–15. [CrossRef]
85. Weigel-Kelley, K.A.; Yoder, M.C.; Srivastava, A. α5β1 integrin as a cellular coreceptor for human parvovirus
B19: Requirement of functional activation of β1 integrin for viral entry. Blood 2003, 102, 3927–3933. [CrossRef]
[PubMed]
86. Munakata, Y.; Saito-Ito, T.; Kumura-Ishii, K.; Huang, J.; Kodera, T.; Ishii, T.; Hirabayashi, Y.; Koyanagi, Y.;
Sasaki, T. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005,
106, 3449–3456. [CrossRef]
87. Bönsch, C.; Kempf, C.; Ros, C. Interaction of parvovirus B19 with human erythrocytes alters virus structure
and cell membrane integrity. J. Virol. 2008, 82, 11784–11791. [CrossRef]
88. Xu, D.; Zhang, Y. Ab initio protein structure assembly using continuous structure fragments and optimized
knowledge-based force field. Proteins Struct. Funct. Bioinform. 2012, 80, 1715–1735. [CrossRef]
89. Shimomura, S.; Komatsu, N.; Frickhofen, N.; Anderson, S.; Kajigaya, S.; Young, N.S. First continuous
propagation of B19 parvovirus in a cell line. Blood 1992, 79, 18–24. [CrossRef]
90. Miyagawa, E.; Yoshida, T.; Takahashi, H.; Yamaguchi, K.; Nagano, T.; Kiriyama, Y.; Okochi, K.; Sato, H.
Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of
B19 infectivity. J. Virol. Methods 1999, 83, 45–54. [CrossRef]
91. Koury, M.J.; Bondurant, M.C. Maintenance by erythropoietin of viability and maturation of murine erythroid
precursor cells. J. Cell. Physiol. 1988, 137, 65–74. [CrossRef] [PubMed]
92. Koury, M.J.; Bondurant, M.C. Erythropoietin retards DNA breakdown and prevents programmed death in
erythroid progenitor cells. Science 1990, 248, 378–381. [CrossRef] [PubMed]
93. Pop, R.; Shearstone, J.R.; Shen, Q.; Liu, Y.; Hallstrom, K.; Koulnis, M.; Gribnau, J.; Socolovsky, M. A key
commitment step in erythropoiesis is synchronized with the cell cycle clock through mutual inhibition
between PU.1 and S-phase progression. PLoS Biol. 2010, 8, e1000484. [CrossRef] [PubMed]
94. Chen, A.Y.; Kleiboeker, S.; Qiu, J. Productive parvovirus B19 infection of primary human erythroid progenitor
cells at hypoxia is regulated by STAT5A and MEK signaling but not HIFα. PLoS Pathog. 2011, 7, e1002088.
[CrossRef]
95. Ganaie, S.S.; Zou, W.; Xu, P.; Deng, X.; Kleiboeker, S.; Qiu, J. Phosphorylated STAT5 directly facilitates
parvovirus B19 DNA replication in human erythroid progenitors through interaction with the MCM complex.
PLoS Pathog. 2017, 13, 1–27. [CrossRef]
96. An, X.; Schulz, V.P.; Li, J.; Wu, K.; Liu, J.; Xue, F.; Hu, J.; Mohandas, N.; Gallagher, P.G. Global transcriptome
analyses of human and murine terminal erythroid differentiation. Blood 2014, 123, 3466–3477. [CrossRef]
97. Kerr, J.R.; Linden, M.R. Human dependovirus infection. In Parvoviruses; Hodder Arnold, Oxford University
Press: London, UK, 2006; pp. 381–384.
Viruses 2020, 12, 1463 18 of 21
98. Guan, W.; Wong, S.; Zhi, N.; Qiu, J. The Genome of Human Parvovirus B19 Can Replicate in Nonpermissive
Cells with the Help of Adenovirus Genes and Produces Infectious Virus. J. Virol. 2009, 83, 9541–9553.
[CrossRef]
99. Winter, K.; von Kietzell, K.; Heilbronn, R.; Pozzuto, T.; Fechner, H.; Weger, S. Roles of E4orf6 and VA I
RNA in Adenovirus-Mediated Stimulation of Human Parvovirus B19 DNA Replication and Structural Gene
Expression. J. Virol. 2012, 86, 5099–5109. [CrossRef]
100. Doerig, C.; Hirt, B.; Antonietti, J.P.; Beard, P. Nonstructural protein of parvoviruses B19 and minute virus of
mice controls transcription. J. Virol. 1990, 64, 387–396. [CrossRef]
101. Ponnazhagan, S.; Woody, M.J.; Wang, X.S.; Zhou, S.Z.; Srivastava, A. Transcriptional transactivation of
parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2. J. Virol. 1995, 69, 8096–8101.
[CrossRef]
102. Ozawa, K.; Ayub, J.; Hao, Y.S.; Kurtzman, G.; Shimada, T.; Young, N. Novel transcription map for the B19
(human) pathogenic parvovirus. J. Virol. 1987, 61, 2395–2406. [CrossRef] [PubMed]
103. Von Kietzell, K.; Pozzuto, T.; Heilbronn, R.; Grössl, T.; Fechner, H.; Weger, S. Antibody-Mediated Enhancement
of Parvovirus B19 Uptake into Endothelial Cells Mediated by a Receptor for Complement Factor C1q. J. Virol.
2014, 88, 8102–8115. [CrossRef] [PubMed]
104. Quattrocchi, S.; Ruprecht, N.; Bnsch, C.; Bieli, S.; Zürcher, C.; Boller, K.; Kempf, C.; Ros, C. Characterization
of the early steps of human parvovirus B19 infection. J. Virol. 2012, 86, 9274–9284. [CrossRef]
105. Dennis, E.A.; Cao, J.; Hsu, Y.H.; Magrioti, V.; Kokotos, G. Phospholipase A2 enzymes: Physical structure,
biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev. 2011,
111, 6130–6185. [CrossRef] [PubMed]
106. Canaan, S.; Zádori, Z.; Ghomashchi, F.; Bollinger, J.; Sadilek, M.; Moreau, M.E.; Tijssen, P.; Gelb, M.H.
Interfacial Enzymology of Parvovirus Phospholipases A2. J. Biol. Chem. 2004, 279, 14502–14508. [CrossRef]
107. Deng, X.; Dong, Y.; Yi, Q.; Huang, Y.; Zhao, D.; Yang, Y.; Tijssen, P.; Qiu, J.; Liu, K.; Li, Y. The Determinants
for the Enzyme Activity of Human Parvovirus B19 Phospholipase A2 (PLA2) and Its Influence on Cultured
Cells. PLoS ONE 2013, 8, e61440. [CrossRef]
108. Lupescu, A.; Bock, C.-T.; Lang, P.A.; Aberle, S.; Kaiser, H.; Kandolf, R.; Lang, F. Phospholipase A2
Activity-Dependent Stimulation of Ca2+ Entry by Human Parvovirus B19 Capsid Protein VP1. J. Virol. 2006,
80, 11370–11380. [CrossRef]
109. Almilaji, A.; Szteyn, K.; Fein, E.; Pakladok, T.; Munoz, C.; Elvira, B.; Towhid, S.T.; Alesutan, I.; Shumilina, E.;
Bock, C.T.; et al. Down-regulation of Na/K + ATPase activity by human parvovirus B19 capsid protein VP1.
Cell. Physiol. Biochem. 2013, 31, 638–648. [CrossRef]
110. Ahmed, M.; Almilaji, A.; Munoz, C.; Elvira, B.; Shumilina, E.; Bock, C.T.; Kandolf, R.; Lang, F. Down-regulation
of K+ channels by human parvovirus B19 capsid protein VP1. Biochem. Biophys. Res. Commun. 2014,
450, 1396–1401. [CrossRef]
111. Ahmed, M.; Honisch, S.; Pelzl, L.; Fezai, M.; Hosseinzadeh, Z.; Bock, C.T.; Kandolf, R.; Lang, F. Up-regulation
of epithelial Na+ channel ENaC by human parvovirus B19 capsid protein VP1. Biochem. Biophys. Res. Commun.
2015, 468, 179–184. [CrossRef]
112. Lu, J.; Zhi, N.; Wong, S.; Brown, K.E. Activation of Synoviocytes by the Secreted Phospholipase A2 Motif in
the VP1-Unique Region of Parvovirus B19 Minor Capsid Protein. J. Infect. Dis. 2006, 193, 582–590. [CrossRef]
[PubMed]
113. Lange, A.; Mills, R.E.; Lange, C.J.; Stewart, M.; Devine, S.E.; Corbett, A.H. Classical nuclear localization
signals: Definition, function, and interaction with importin α. J. Biol. Chem. 2007, 282, 5101–5105. [CrossRef]
114. Panté, N.; Kann, M. Nuclear pore complex is able to transport macromolecules with diameters of ∼39 nm.
Mol. Biol. Cell 2002, 13, 425–434. [CrossRef] [PubMed]
115. Mäntylä, E.; Aho, V.; Kann, M.; Vihinen-Ranta, M. Cytoplasmic Parvovirus Capsids Recruit Importin Beta
for Nuclear Delivery. J. Virol. 2020, 94, e01532-19. [CrossRef]
116. Pillet, S.; Annan, Z.; Fichelson, S.; Morinet, F. Identification of a nonconventional motif necessary for the
nuclear import of the human parvovirus B19 major capsid protein (VP2). Virology 2003, 306, 25–32. [CrossRef]
117. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. 84 Nat nanotech 2007 R Langer
Nanocarriers as an emerging platform for cancer therapy.pdf. Nat. Nanotechnol. 2007, 2, 751–760. [CrossRef]
118. Wilhelm, S.; Tavares, A.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H.F.; Chan, W.C.W. Analysis of nanoparticle
delivery to tumours. Nat. Rev. Mater. 2016, 1, 16014. [CrossRef]
Viruses 2020, 12, 1463 19 of 21
119. Ma, Y.; Nolte, R.J.M.; Cornelissen, J.J.L.M. Virus-based nanocarriers for drug delivery. Adv. Drug Deliv. Rev.
2012, 64, 811–825. [CrossRef]
120. Somiya, M.; Liu, Q.; Kuroda, S. Current progress of virus-mimicking nanocarriers for drug delivery.
Nanotheranostics 2017, 1, 415–429. [CrossRef]
121. Stachon, A.; Holland-Letz, T.; Krieg, M. High in-hospital mortality of intensive care patients with nucleated
red blood cells in blood. Clin. Chem. Lab. Med. 2004, 42, 933–938. [CrossRef]
122. Stachon, A.; Kempf, R.; Holland-Letz, T.; Friese, J.; Becker, A.; Krieg, M. Daily monitoring of nucleated red
blood cells in the blood of surgical intensive care patients. Clin. Chim. Acta 2006, 366, 329–335. [CrossRef]
[PubMed]
123. Buttarello, M.; Plebani, M. Automated blood cell counts: State of the art. Am. J. Clin. Pathol. 2008, 130,
104–116. [CrossRef] [PubMed]
124. Koury, M.J. Abnormal erythropoiesis and the pathophysiology of chronic anemia. Blood Rev. 2014, 28, 49–66.
[CrossRef] [PubMed]
125. Danise, P.; Maconi, M.; Barrella, F.; Di Palma, A.; Avino, D.; Rovetti, A.; Gioia, M.; Amendola, G. Evaluation
of nucleated red blood cells in the peripheral blood of hematological diseases. Clin. Chem. Lab. Med. 2011,
50, 357–360. [CrossRef]
126. Buoro, S.; Vavassori, M.; Pipitone, S.; Benegiamo, A.; Lochis, E.; Fumagalli, S.; Falanga, A.; Marchetti, M.;
Crippa, A.; Ottomano, C.; et al. Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients
with thalassaemia or sickle cell anaemia and in neonates. Blood Transfus. 2015, 13, 588–594. [CrossRef]
127. Constantino, B.T.; Cogionis, B. Nucleated RBCs—Significance in the peripheral blood film. Lab. Med. 2000,
31, 223–229. [CrossRef]
128. Da Rin, G.; Vidali, M.; Balboni, F.; Benegiamo, A.; Borin, M.; Ciardelli, M.L.; Dima, F.; Di Fabio, A.; Fanelli, A.;
Fiorini, F.; et al. Performance evaluation of the automated nucleated red blood cell count of five commercial
hematological analyzers. Int. J. Lab. Hematol. 2017, 39, 663–670. [CrossRef]
129. Anagnostou, A.; Liu, Z.; Steiner, M.; Chin, K.; Lee, E.S.; Kessimian, N.; Noguchi, C.T. Erythropoietin receptor
mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 1994, 91, 3974–3978. [CrossRef]
130. Spivak, J.L. The anaemia of cancer: Death by a thousand cuts. Nat. Rev. Cancer 2005, 5, 543–555. [CrossRef]
131. Jelkmann, W.; Bohlius, J.; Hallek, M.; Sytkowski, A.J. The erythropoietin receptor in normal and cancer
tissues. Crit. Rev. Oncol. Hematol. 2008, 67, 39–61. [CrossRef]
132. Chen, K.; Liu, J.; Heck, S.; Chasis, J.A.; An, X.; Mohandas, N. Resolving the distinct stages in erythroid
differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc. Natl.
Acad. Sci. USA 2009, 106, 17413–17418. [CrossRef]
133. Hu, J.; Liu, J.; Xue, F.; Halverson, G.; Reid, M.; Guo, A.; Chen, L.; Raza, A.; Galili, N.; Jaffray, J.; et al. Isolation
and functional characterization of human erythroblasts at distinct stages: Implications for understanding of
normal and disordered erythropoiesis in vivo. Blood 2013, 121, 3246–3253. [CrossRef] [PubMed]
134. MacHherndl-Spandl, S.; Suessner, S.; Danzer, M.; Proell, J.; Gabriel, C.; Lauf, J.; Sylie, R.; Klein, H.U.;
Béné, M.C.; Weltermann, A.; et al. Molecular pathways of early CD105-positive erythroid cells as compared
with CD34-positive common precursor cells by flow cytometric cell-sorting and gene expression profiling.
Blood Cancer J. 2013, 3, 1–13. [CrossRef]
135. Origa, R. β-Thalassemia. Genet. Med. 2017, 19, 609–619. [CrossRef] [PubMed]
136. Kato, G.J.; Piel, F.B.; Reid, C.D.; Gaston, M.H.; Ohene-Frempong, K.; Krishnamurti, L.; Smith, W.R.;
Panepinto, J.A.; Weatherall, D.J.; Costa, F.F.; et al. Sickle cell disease. Nat. Rev. Dis. Prim. 2018, 4, 1–22.
[CrossRef] [PubMed]
137. Bayanzay, K.; Alzoebie, L. Reducing the iron burden and improving survival in transfusion-dependent
thalassemia patients: Current perspectives. J. Blood Med. 2016, 7, 159–169. [CrossRef] [PubMed]
138. Coates, T.D.; Wood, J.C. How we manage iron overload in sickle cell patients. Br. J. Haematol. 2017,
177, 703–716. [CrossRef]
139. Peters, C. Allogeneic Hematopoietic Stem Cell Transplantation to Cure Transfusion-Dependent Thalassemia:
Timing Matters! Biol. Blood Marrow Transpl. 2018, 24, 1107–1108. [CrossRef]
140. Gluckman, G.; Cappelli, B.; Bernaudin, F.; Labopin, M.; Volt, F.; Carreras, J.; Pinto Simoes, B.; Ferster, A.;
Dupont, S.; de la Fuente, J.; et al. Sickle cell disease: An international survey of results of HLA-identical
sibling hematopoietic stem cell transplantation. Blood 2017, 129, 1548–1556. [CrossRef]
Viruses 2020, 12, 1463 20 of 21
141. Karponi, G.; Zogas, N. Gene therapy for beta-thalassemia: Updated perspectives. Appl. Clin. Genet. 2019,
12, 167–180. [CrossRef]
142. Lidonnici, M.R.; Ferrari, G. Gene therapy and gene editing strategies for hemoglobinopathies. Blood Cells
Mol. Dis. 2018, 70, 87–101. [CrossRef] [PubMed]
143. Lino, C.A.; Harper, J.C.; Carney, J.P.; Timlin, J.A. Delivering crispr: A review of the challenges and approaches.
Drug Deliv. 2018, 25, 1234–1257. [CrossRef] [PubMed]
144. Chery, J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdr. J. 2016,
4, 35–50. [CrossRef] [PubMed]
145. Galaway, F.A.; Stockley, P.G. MS2 viruslike particles: A robust, semisynthetic targeted drug delivery platform.
Mol. Pharm. 2013, 10, 59–68. [CrossRef] [PubMed]
146. Ashley, C.E.; Carnes, E.C.; Phillips, G.K.; Durfee, P.N.; Buley, M.D.; Lino, C.A.; Padilla, D.P.; Phillips, B.;
Carter, M.B.; Willman, C.L.; et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like
particles. ACS Nano 2011, 5, 5729–5745. [CrossRef] [PubMed]
147. Nai, A.; Lidonnici, M.R.; Rausa, M.; Mandelli, G.; Pagani, A.; Silvestri, L.; Ferrari, G.; Camaschella, C.
The second transferrin receptor regulates red blood cell production in mice. Blood 2015, 125, 1170–1179.
[CrossRef]
148. Artuso, I.; Lidonnici, M.R.; Altamura, S.; Mandelli, G.; Pettinato, M.; Muckenthaler, M.U.; Silvestri, L.;
Ferrari, G.; Camaschella, C.; Nai, A. Transferrin receptor 2 is a potential novel therapeutic target for
β-thalassemia: Evidence from a murine model. Blood 2018, 132, 2286–2297. [CrossRef]
149. Casu, C.; Pettinato, M.; Liu, A.; Aghajan, M.; Lo Presti, V.; Lidonnici, M.R.; Munoz, K.A.; O’Hara, E.;
Olivari, V.; Di Modica, S.M.; et al. Correcting β-thalassemia by combined therapies that restrict iron and
modulate erythropoietin activity. Blood 2020, 136, 1968–1979. [CrossRef]
150. Lohani, N.; Bhargava, N.; Munshi, A.; Ramalingam, S. Pharmacological and molecular approaches for the
treatment of β-hemoglobin disorders. J. Cell. Physiol. 2018, 233, 4563–4577. [CrossRef]
151. Hasserjian, R.P.; Zuo, Z.; Garcia, C.; Tang, G.; Kasyan, A.; Luthra, R.; Abruzzo, L.V.; Kantarjian, H.M.;
Medeiros, L.J.; Wang, S.A. Acute erythroid leukemia: A reassessment using criteria refined in the 2008 WHO
classification. Blood 2010, 115, 1985–1992. [CrossRef]
152. Wickrema, A.; Crispino, J.D. Erythroid and megakaryocytic transformation. Oncogene 2007, 26, 6803–6815.
[CrossRef] [PubMed]
153. Mazzella, F.M.; Kowal-Vern, A.; Atef Shrit, M.; Rector, J.T.; Cotelingam, J.D.; Schumacher, H.R. Effects of
multidrug resistance gene expression in acute erythroleukemia. Mod. Pathol. 2000, 13, 407–413. [CrossRef]
[PubMed]
154. Schwartz, R.S. Paul Ehrlich’s magic bullets. N. Engl. J. Med. 2004, 350, 1079–1080. [CrossRef]
155. Boddu, P.; Benton, C.B.; Wang, W.; Borthakur, G.; Khoury, J.D.; Pemmaraju, N. Erythroleukemia-historical
perspectives and recent advances in diagnosis and management. Blood Rev. 2018, 32, 96–105. [CrossRef]
[PubMed]
156. Leisi, R.; Von Nordheim, M.; Kempf, C.; Ros, C. Specific targeting of proerythroblasts and erythroleukemic
cells by the VP1u region of parvovirus B19. Bioconjug. Chem. 2015, 26, 1923–1930. [CrossRef]
157. Rapti, K.; Louis-Jeune, V.; Kohlbrenner, E.; Ishikawa, K.; Ladage, D.; Zolotukhin, S.; Hajjar, R.J.; Weber, T.
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.
Mol. Ther. 2012, 20, 73–83. [CrossRef]
158. Rutledge, E.A.; Halbert, C.L.; Russell, D.W. Infectious Clones and Vectors Derived from Adeno-Associated
Virus (AAV) Serotypes Other Than AAV Type 2. J. Virol. 1998, 72, 309–319. [CrossRef]
159. Gao, G.; Vandenberghe, L.H.; Alvira, M.R.; Lu, Y.; Calcedo, R.; Zhou, X.; Wilson, J.M. Clades of
Adeno-Associated Viruses Are Widely Disseminated in Human Tissues. J. Virol. 2004, 78, 6381–6388.
[CrossRef]
160. Zinn, E.; Pacouret, S.; Khaychuk, V.; Turunen, H.T.; Carvalho, L.S.; Andres-Mateos, E.; Shah, S.; Shelke, R.;
Maurer, A.C.; Maurer, E.; et al. In silico reconstruction of the viral evolutionary lineage yields a potent gene
therapy vector. Cell Rep. 2015, 12, 1056–1068. [CrossRef]
161. Yeh, P.; Landais, D.; Lemaître, M.; Maury, I.; Crenne, J.Y.; Becquart, J.; Murry-Brelier, A.; Boucher, F.;
Montay, G.; Fleer, R.; et al. Design of yeast-secreted albumin derivatives for human therapy: Biological
and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc. Natl. Acad. Sci. USA 1992,
89, 1904–1908. [CrossRef]
Viruses 2020, 12, 1463 21 of 21
162. Czajkowsky, D.M.; Hu, J.; Shao, Z.; Pleass, R.J. Fc-fusion proteins: New developments and future perspectives.
EMBO Mol. Med. 2012, 4, 1015–1028. [CrossRef] [PubMed]
163. Shen, B.Q.; Xu, K.; Liu, L.; Raab, H.; Bhakta, S.; Kenrick, M.; Parsons-Reponte, K.L.; Tien, J.; Yu, S.F.;
Mai, E.; et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug
conjugates. Nat. Biotechnol. 2012, 30, 184–189. [CrossRef] [PubMed]
164. Wu, M.; Brown, W.L.; Stockley, P.G. Cell-Specific Delivery of Bacteriophage-Encapsidated Ricin a Chain.
Bioconjug. Chem. 1995, 6, 587–595. [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
